Scientists started studying data from the day Italy's vaccination campaign began, on Dec. 27 2020, until May 3 2021.
As of Saturday morning, some 8.3 million Italians, or 14% of the population, were completely vaccinated, while around 10 million people had received a first jab.
The EMA's approval for the vaccine is based on the second dose being administered between four and 12 weeks after the first. A 16-week interval has not been tested in any human trials.
Spain's state-backed Carlos III Health Institute is investigating the effects of giving Pfizer and BioNTech's vaccine to patients who already received an AstraZeneca shot.
Francine Boyer, 54, is the first Canadian fatality linked to the AstraZeneca vaccine. She received a shot on April 9 and died on April 23 in hospital where she was being treated for fatigue and headaches, her husband said in a statement.
"I have tremendous confidence in all vaccines, including AstraZeneca," said Trudeau, who got his first AstraZeneca shot last Friday.
AstraZeneca said in response that the legal action by the EU was without merit and pledged to defend itself strongly in court.
"The Commission has started last Friday a legal action against AstraZeneca," the EU spokesman told a news conference, noting all 27 EU states backed the move.
The decision, which would remove the shot from Denmark's vaccination scheme, could delay the country's vaccine rollout by up to four weeks, based on previous statements by health bodies.
A spate of countries across the world, including France and Germany, have resumed administering the shot to some age groups, mostly those above 50 or 60.
Europe's medicines regulator said this week it found rare cases of blood clots among some adult recipients of the shot, although the vaccine's advantages still outweighed its risks.
Greece has reported 288,230 cases of COVID-19 and a total of 8,680 deaths. It has administered 378,997 doses of the AstraZeneca vaccine so far and ordered another 1.35 million doses.
The French decision came after European drug regulators said on Wednesday there was a possible link between AstraZeneca's COVID-19 shot and a very small number of cases of rare blood clots.
"This is a logical choice and one of security," Dominique Le Guludec, the head of the HAS, told reporters.
His comments came as the European Medicines Agency and Britain's medical regulator acknowledged a possible link between the AstraZeneca vaccine to very rare cases of unusual blood clots with low blood platelets, with most cases reported in women under 60 years of age within two weeks of vaccination.
Taiwan, which has kept the pandemic under control thanks to early and effective prevention, began its vaccination campaign only last month, also with AstraZeneca shots, after getting 117,000 doses directly from the drugmaker.
Chen told reporters that the latest vaccines were also manufactured in South Korea and had been due to start arriving from February, but had been held up by global vaccine supply problems.
The decision was made following new reports from medicine monitoring agency Lareb and discussions with health authorities, a Health Ministry statement said.
"Authorities in the UK, European Union, the World Health Organization have concluded that the benefits of using our vaccine to protect people from this deadly virus significantly outweigh the risks across all adult age groups," it said.
The vaccine is of great use for the elderly, among whom many fall seriously ill each day.
"At the same time, we haven't seen these rare and serious side effects among our elderly. That is the background to why we are lifting the suspension for people older than 65."
New infections are surging in Hungary in a third wave of the pandemic, even as vaccine import and usage rates are among the highest in the EU with the country using Chinese and Russian vaccines as well as Western ones.
"We are in a race against time," Surgeon General Cecilia Muller told a news briefing. "We will overturn the four corners of the world for as many doses of proper efficient and safe vaccines as possible."
The institute said it estimated that the investigation would take at least one week. It said earlier this week that it had received any reports of cases of blood clots among people who had taken the AstraZeneca vaccine in Finland.
"As the MHRA (Britain's Medicines and Healthcare Products Regulatory Agency) has said, blood clots occur naturally but there is no evidence that they are any more likely to occur following vaccination, so as such there's no evidence of any causal link between blood clots and the AZ vaccine," he told reporters.
The decision means that all people aged over 18 can now receive the shot, the DGS authority said, after it was approved for those under 65 in late January.
Portugal, a nation of just over 10 million people, faced a tough battle against the pandemic in January, but the number of daily infections and fatalities has dropped sharply since then.